Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Interferon-gamma release assays have suboptimal sensitivity in both latent and active tuberculosis.

Goetzinger F, Burkhardt I, Villanueva P, Clifford V, Curtis N, Tebruegge M.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):766-767. doi: 10.5588/ijtld.18.0603. No abstract available.

PMID:
31315713
2.

Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children-A Systematic Review and Meta-Analysis.

Meier NR, Volken T, Geiger M, Heininger U, Tebruegge M, Ritz N.

Front Pediatr. 2019 May 29;7:208. doi: 10.3389/fped.2019.00208. eCollection 2019.

3.

Advanced immunodiagnostic tests for paediatric tuberculosis.

Villanueva P, Sudbury E, Song R, Tebruegge M, Curtis N.

Lancet Infect Dis. 2019 May;19(5):467-468. doi: 10.1016/S1473-3099(19)30175-6. No abstract available.

PMID:
31034388
4.

Mycobacteria-Specific Mono- and Polyfunctional CD4+ T Cell Profiles in Children With Latent and Active Tuberculosis: A Prospective Proof-of-Concept Study.

Tebruegge M, Ritz N, Donath S, Dutta B, Forbes B, Clifford V, Zufferey C, De Rose R, Robins-Browne RM, Hanekom W, Graham SM, Connell T, Curtis N.

Front Immunol. 2019 Apr 5;10:431. doi: 10.3389/fimmu.2019.00431. eCollection 2019.

5.

Calcineurin Inhibitors and Variation in the Performance of Interferon-γ Release Assays Used to Detect Tuberculosis Infection.

Barton E, Gao Y, Ball D, Fidler K, Klein N, Curtis N, Clifford V, Marshall BG, Chancellor A, Mansour S, Elkington P, Tebruegge M.

Ann Am Thorac Soc. 2019 Jun;16(6):771-775. doi: 10.1513/AnnalsATS.201811-784RL. No abstract available.

PMID:
30811214
6.

Interpretation and management of discordant tuberculin skin test and interferon-gamma release assays results in children.

Volkman T, Graham H, Laemmle-Ruff I, Tosif S, Tebruegge M, Ranganathan S, Curtis N.

J Paediatr Child Health. 2019 Feb;55(2):247-248. doi: 10.1111/jpc.14338. No abstract available.

PMID:
30746877
7.

Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting.

Clifford V, Tebruegge M, Zufferey C, Germano S, Forbes B, Cosentino L, Matchett E, McBryde E, Eisen D, Robins-Browne R, Street A, Denholm J, Curtis N.

Tuberculosis (Edinb). 2019 Jan;114:91-102. doi: 10.1016/j.tube.2018.08.011. Epub 2018 Aug 25.

PMID:
30711163
8.

Performance of Tuberculin Skin Tests and Interferon-γ Release Assays in Children Younger Than 5 Years.

Velasco-Arnaiz E, Soriano-Arandes A, Latorre I, Altet N, Domínguez J, Fortuny C, Monsonís M, Tebruegge M, Noguera-Julian A.

Pediatr Infect Dis J. 2018 Dec;37(12):1235-1241. doi: 10.1097/INF.0000000000002015.

PMID:
30408005
9.

Seasonal variation in the performance of QuantiFERON-TB Gold In-Tube assays used for the diagnosis of tuberculosis infection.

Tebruegge M, Curtis N, Clifford V, Fernandez-Turienzo C, Klein N, Fidler K, Mansour S, Elkington P, Morris-Jones S.

Tuberculosis (Edinb). 2018 May;110:26-29. doi: 10.1016/j.tube.2018.03.002. Epub 2018 Mar 8.

PMID:
29779769
10.

Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.

Villanueva P, Neth O, Ritz N, Tebruegge M; Paediatric Tuberculosis Network European Trials Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800346. doi: 10.1183/13993003.00346-2018. Print 2018 May. No abstract available.

11.

The Impact of Pediatric Outpatient Parenteral Antibiotic Therapy Implementation at a Tertiary Children's Hospital in the United Kingdom.

Patel S, Burzio V, Green H, Rees S, Tebruegge M, Jones C, Faust SN.

Pediatr Infect Dis J. 2018 Dec;37(12):e292-e297. doi: 10.1097/INF.0000000000002031.

PMID:
29613971
12.

Cytokine diagnosis of pleural TB: will it stand the test of time?

Tebruegge M, Elkington PT.

Thorax. 2018 Mar;73(3):206-207. doi: 10.1136/thoraxjnl-2017-210918. Epub 2017 Dec 20. No abstract available.

PMID:
29263234
13.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

14.

CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains.

Chancellor A, Tocheva AS, Cave-Ayland C, Tezera L, White A, Al Dulayymi JR, Bridgeman JS, Tews I, Wilson S, Lissin NM, Tebruegge M, Marshall B, Sharpe S, Elliott T, Skylaris CK, Essex JW, Baird MS, Gadola S, Elkington P, Mansour S.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10956-E10964. doi: 10.1073/pnas.1708252114. Epub 2017 Nov 20.

15.

D-methionine interferes with non-typeable Haemophilus influenzae peptidoglycan synthesis during growth and biofilm formation.

Dawe H, Berger E, Sihlbom C, Angus EM, Howlin RP, Laver JR, Tebruegge M, Hall-Stoodley L, Stoodley P, Faust SN, Allan RN.

Microbiology. 2017 Jul;163(7):1093-1104. doi: 10.1099/mic.0.000491. Epub 2017 Jul 21.

PMID:
28699879
16.

Nontuberculous mycobacterial disease in childhood - update on diagnostic approaches and treatment.

Zimmermann P, Curtis N, Tebruegge M.

J Infect. 2017 Jun;74 Suppl 1:S136-S142. doi: 10.1016/S0163-4453(17)30204-9. Review.

PMID:
28646953
17.

Management of child MDR-TB contacts across countries in the WHO European Region: a survey of current practice.

Turkova A, Tebruegge M, Brinkmann F, Tsolia M, Mouchet F, Kampmann B, Seddon JA.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):774-777. doi: 10.5588/ijtld.16.0949.

18.

Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection.

Chancellor A, White A, Tocheva AS, Fenn JR, Dennis M, Tezera L, Singhania A, Elliott T, Tebruegge M, Elkington P, Gadola S, Sharpe S, Mansour S.

Tuberculosis (Edinb). 2017 Jul;105:86-95. doi: 10.1016/j.tube.2017.04.011. Epub 2017 Apr 28.

19.

Mycobacteria-specific cytokine responses as correlates of treatment response in active and latent tuberculosis.

Clifford V, Tebruegge M, Zufferey C, Germano S, Forbes B, Cosentino L, McBryde E, Eisen D, Robins-Browne R, Street A, Denholm J, Curtis N.

J Infect. 2017 Aug;75(2):132-145. doi: 10.1016/j.jinf.2017.04.011. Epub 2017 May 5.

PMID:
28483404
20.

Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis.

Edwards A, Gao Y, Allan RN, Ball D, de Graaf H, Coelho T, Clifford V, Curtis N, Williams A, Faust SN, Mansour S, Marshall B, Elkington P, Tebruegge M.

Thorax. 2017 Oct;72(10):946-949. doi: 10.1136/thoraxjnl-2016-209397. Epub 2017 Feb 3.

PMID:
28159773
21.

Dissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional model.

Tezera LB, Bielecka MK, Chancellor A, Reichmann MT, Shammari BA, Brace P, Batty A, Tocheva A, Jogai S, Marshall BG, Tebruegge M, Jayasinghe SN, Mansour S, Elkington PT.

Elife. 2017 Jan 7;6. pii: e21283. doi: 10.7554/eLife.21283.

22.

The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe - A Paediatric Tuberculosis Network European Trials Group (ptbnet) survey.

Kontturi A, Santiago B, Tebruegge M, von Both U, Salo E, Ritz N; Ptbnet BCG shortage project collaborators, on behalf of the Paediatric Tuberculosis Network European Trials Group (ptbnet).

Tuberculosis (Edinb). 2016 Dec;101:125-129. doi: 10.1016/j.tube.2016.08.005. Epub 2016 Aug 31.

PMID:
27865381
23.

Tuberculosis: An Infection-Initiated Autoimmune Disease?

Elkington P, Tebruegge M, Mansour S.

Trends Immunol. 2016 Dec;37(12):815-818. doi: 10.1016/j.it.2016.09.007. Epub 2016 Oct 21.

24.

European shortage of purified protein derivative and its impact on tuberculosis screening practices.

Tebruegge M, Buonsenso D, Brinkmann F, Noguera-Julian A, Pavić I, Arbore AS, Vančíková Z, Velizarova S, Welch SB, Ritz N; Paediatric Tuberculosis Network European Trials Group (ptbnet).

Int J Tuberc Lung Dis. 2016 Oct;20(10):1293-1299.

PMID:
27725037
25.

A personalised approach is needed for the management of non-tuberculous mycobacterial cervicofacial lymphadenitis.

Zimmermann P, Tebruegge M, Curtis N, Ritz N.

J Infect. 2016 Oct;73(4):391-2. doi: 10.1016/j.jinf.2016.07.017. Epub 2016 Aug 6. No abstract available.

PMID:
27506394
26.

Interferon-gamma Release Assays Should Not Replace Tuberculin Skin Tests in Screening Programs for Children.

Tebruegge M, Clifford V, Curtis N.

Pediatr Infect Dis J. 2016 Aug;35(8):929. doi: 10.1097/INF.0000000000001195. No abstract available.

PMID:
27416010
27.

Comparable CD4 and CD8 T cell responses and cytokine release after at-birth and delayed BCG immunisation in infants born in Australia.

Ritz N, Casalaz D, Donath S, Tebruegge M, Dutta B, Connell TG, Robins-Browne R, Britton WJ, Hanekom WA, Curtis N.

Vaccine. 2016 Jul 29;34(35):4132-4139. doi: 10.1016/j.vaccine.2016.06.077. Epub 2016 Jul 5.

PMID:
27396518
28.

Severe Enterovirus Infections in Hospitalized Children in the South of England: Clinical Phenotypes and Causative Genotypes.

de Graaf H, Pelosi E, Cooper A, Pappachan J, Sykes K, MacIntosh I, Gbesemete D, Clark TW, Patel SV, Faust SN, Tebruegge M.

Pediatr Infect Dis J. 2016 Jul;35(7):723-7. doi: 10.1097/INF.0000000000001093.

29.

Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis & Management at a Tertiary Center.

Tebruegge M, Pantazidou A, MacGregor D, Gonis G, Leslie D, Sedda L, Ritz N, Connell T, Curtis N.

PLoS One. 2016 Jan 26;11(1):e0147513. doi: 10.1371/journal.pone.0147513. eCollection 2016.

30.

Tuberculosis in young refugees.

Ritz N, Brinkmann F, Santiago Garcia B, Tebruegge M, Kampmann B; Paediatric Tuberculosis Network European Trials group (ptbnet).

Lancet. 2015 Dec 19;386(10012):2475-6. doi: 10.1016/S0140-6736(15)01241-6. Epub 2015 Dec 18. No abstract available.

PMID:
26738710
31.

Respiratory tract infection associated with seizures.

Brendish NJ, Williams S, Faust SN, Tebruegge M.

BMJ. 2015 Sep 4;351:h4659. doi: 10.1136/bmj.h4659. No abstract available.

PMID:
26341102
32.

Serum IP-10 in the diagnosis of latent and active tuberculosis.

Clifford V, Tebruegge M, Zufferey C, Germano S, Denholm J, Street A, McBryde E, Eisen D, Curtis N.

J Infect. 2015 Dec;71(6):696-8. doi: 10.1016/j.jinf.2015.08.001. Epub 2015 Aug 10. No abstract available.

PMID:
26271898
33.

Current status of Bacille Calmette Guérin (BCG) immunisation in Europe - A ptbnet survey and review of current guidelines.

Dierig A, Tebruegge M, Krivec U, Heininger U, Ritz N; Paediatric Tuberculosis Network European Trials group (ptbnet).

Vaccine. 2015 Sep 11;33(38):4994-9. doi: 10.1016/j.vaccine.2015.06.097. Epub 2015 Jul 4.

PMID:
26151543
34.

Diagnostic Tests for Childhood Tuberculosis: Past Imperfect, Present Tense and Future Perfect?

Tebruegge M, Ritz N, Curtis N, Shingadia D.

Pediatr Infect Dis J. 2015 Sep;34(9):1014-9. doi: 10.1097/INF.0000000000000796. Review. No abstract available.

PMID:
26107342
35.

Mycobacteria-Specific Cytokine Responses Detect Tuberculosis Infection and Distinguish Latent from Active Tuberculosis.

Tebruegge M, Dutta B, Donath S, Ritz N, Forbes B, Camacho-Badilla K, Clifford V, Zufferey C, Robins-Browne R, Hanekom W, Graham SM, Connell T, Curtis N.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):485-99. doi: 10.1164/rccm.201501-0059OC.

PMID:
26030187
36.

Limitations of current tuberculosis screening tests in immunosuppressed patients.

Clifford V, Tebruegge M, Curtis N.

BMJ. 2015 Apr 28;350:h2226. doi: 10.1136/bmj.h2226. No abstract available.

PMID:
25921753
37.

Environmental temperature impacts on the performance of QuantiFERON-TB Gold In-Tube assays.

Jarvis J, Gao Y, de Graaf H, Hughes S, Allan RN, Williams A, Marshall B, Elkington P, Faust SN, Tebruegge M.

J Infect. 2015 Aug;71(2):276-80. doi: 10.1016/j.jinf.2015.04.004. Epub 2015 Apr 11. No abstract available.

PMID:
25869537
38.

The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in QuantiFERON-TB Gold In Tube assays.

Clifford V, Zufferey C, Germano S, Ryan N, Leslie D, Street A, Denholm J, Tebruegge M, Curtis N.

Tuberculosis (Edinb). 2015 May;95(3):343-9. doi: 10.1016/j.tube.2015.02.039. Epub 2015 Feb 14.

PMID:
25837441
39.

Cytokines for monitoring anti-tuberculous therapy: A systematic review.

Clifford V, Zufferey C, Street A, Denholm J, Tebruegge M, Curtis N.

Tuberculosis (Edinb). 2015 May;95(3):217-28. doi: 10.1016/j.tube.2015.01.003. Epub 2015 Jan 30. Review.

PMID:
25797612
40.

The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis.

Zimmermann P, Tebruegge M, Curtis N, Ritz N.

J Infect. 2015 Jul;71(1):9-18. doi: 10.1016/j.jinf.2015.02.010. Epub 2015 Feb 26. Review.

PMID:
25727993
41.

Shortage of purified protein derivative for tuberculosis testing.

Tebruegge M, Bogyi M, Soriano-Arandes A, Kampmann B; Paediatric Tuberculosis Network European Trials Group.

Lancet. 2014 Dec 6;384(9959):2026. doi: 10.1016/S0140-6736(14)62335-7. No abstract available. Erratum in: Lancet. 2015 Jan 10;385(9963):e4.

PMID:
25483167
42.

Invasive Propionibacterium acnes infections in a non-selective patient cohort: clinical manifestations, management and outcome.

Tebruegge M, Jones C, de Graaf H, Sukhtankar P, Allan RN, Howlin RP, Browning D, Schuster H, Pallett A, Patel S, Faust SN.

Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):527-34. doi: 10.1007/s10096-014-2256-y. Epub 2014 Oct 18.

PMID:
25326276
43.

Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe.

Tebruegge M, Ritz N, Koetz K, Noguera-Julian A, Seddon JA, Welch SB, Tsolia M, Kampmann B.

PLoS One. 2014 Jun 12;9(6):e99129. doi: 10.1371/journal.pone.0099129. eCollection 2014.

44.

Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results.

Tebruegge M, de Graaf H, Sukhtankar P, Elkington P, Marshall B, Schuster H, Patel S, Faust SN.

J Clin Microbiol. 2014 Jul;52(7):2694-7. doi: 10.1128/JCM.00814-14. Epub 2014 May 14.

45.

Meningoencephalitis due to adenovirus in a healthy infant mimicking severe bacterial sepsis.

Reyes-Andrade J, Sánchez-Céspedes J, Olbrich P, Falcon L, Sanchez-Ganfornina I, Tebruegge M, Pérez-Romero P, Neth O.

Pediatr Infect Dis J. 2014 Apr;33(4):416-9. doi: 10.1097/INF.0000000000000128.

PMID:
24632664
46.

Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children after initiation of antiretroviral therapy.

Gkentzi D, Tebruegge M, Tudor-Williams G, Walters S, Lyall H, Sharland M, Doerholt K.

Pediatr Infect Dis J. 2014 Sep;33(9):953-8. doi: 10.1097/INF.0000000000000331.

PMID:
24618936
47.

Evidence base for the use of corticosteroids in septic shock in children.

de Graaf H, Tebruegge M, Faust SN.

Crit Care Med. 2014 Jan;42(1):e83-4. doi: 10.1097/CCM.0b013e3182a5270c. No abstract available.

PMID:
24346552
48.

Varicella zoster virus central nervous system immune reconstitution inflammatory syndrome presenting in a child.

Iro MA, Kirkham FJ, Macdonald JH, Tebruegge M, Faust SN, Patel SV.

Pediatr Infect Dis J. 2013 Nov;32(11):1283-4. doi: 10.1097/INF.0b013e31829aa4fc.

PMID:
24141801
49.

Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children.

Seddon JA, Perez-Velez CM, Schaaf HS, Furin JJ, Marais BJ, Tebruegge M, Detjen A, Hesseling AC, Shah S, Adams LV, Starke JR, Swaminathan S, Becerra MC; Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

J Pediatric Infect Dis Soc. 2013 Jun;2(2):100-9. doi: 10.1093/jpids/pit012. Epub 2013 Apr 10.

50.

Clostridium difficile in children: a review of existing and recently uncovered evidence.

Morris O, Tebruegge M, Pallett A, Green SM, Pearson AD, Tuck A, Clarke SC, Roderick P, Faust SN.

Adv Exp Med Biol. 2013;764:57-72. Review.

PMID:
23654056

Supplemental Content

Loading ...
Support Center